Related Experiment Video
Updated: Apr 5, 2026
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
1.9K
Lowering cholesterol in chronic kidney disease: is it safe and effective?
Muh Geot Wong1, Christoph Wanner2, John Knight1
1The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, New South Wales 2050, Australia.
European Heart Journal
|August 21, 2015
Summary
Cholesterol-lowering statins benefit early chronic kidney disease (CKD) patients, but their effectiveness and safety in end-stage CKD are debated. This review examines statin risks and benefits for kidney and cardiovascular health in CKD patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Patients with chronic kidney disease (CKD) face elevated cardiovascular disease (CVD) risk.
- Cholesterol lowering is proven to prevent CVD in CKD patients.
- Statin benefits in early CKD are established, but effects in end-stage CKD are controversial.
Purpose of the Study:
- To review current evidence on the benefits and risks of statin therapy.
- To evaluate statin effects on kidney and cardiovascular disease progression in CKD patients.
- To address uncertainties regarding statin heterogeneity and safety in advanced CKD.
Main Methods:
- Review of completed studies and recent research on statin therapy in CKD.
- Analysis of data concerning cardiovascular and renal outcomes.
- Examination of safety profiles, including potential side effects and high-dose concerns.
Main Results:
- Statins demonstrate clear benefits for cardiovascular disease prevention in early CKD.
- Evidence for statin efficacy in end-stage CKD remains inconclusive and debated.
- Potential for heterogeneous effects among different statins and safety concerns with high doses exist.
Conclusions:
- Statin therapy offers established cardiovascular benefits in early CKD.
- Further research is needed to clarify statin efficacy and safety in end-stage CKD.
- Risk-benefit evaluation of statins in CKD is crucial and depends on individual patient risk profiles.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
627
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
627
01:25Chronic Kidney Disease I: Introduction
1.2K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
01:24Chronic Kidney Disease II: Clinical Manifestations
970
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
970
01:18Chronic Kidney Disease IV: Nursing Management
618
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
618
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
317
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
317